New antibiotics for
Serious Drug Resistant Infections

Recent Rib-X News

Yale University Professor and Rib-X Co-Founder Discovers Novel Ribosome Antibiotic Structures That May Lead to New Treatments for Drug-Resistant Infections

Rib-X Appoints MedImmune's Peter Greenleaf to Board

About Us

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics.

Read More…

Pipeline

Delafloxacin

Radezolid

Rχ-02

Rχ-04